Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension

Presentation Author(s):

Atul Deodhar, Victoria Navarro-Compán, Denis Poddubnyy, Lianne S. Gensler, Sofia Ramiro, Tetsuya Tomita, Helena Marzo‑Ortega, Carmen Fleurinck, Thomas Vaux, Ute Massow, Désirée van der Heijde, Xenofon Baraliakos (narrating author)

Abstract or description:

 This study aimed to report the long-term safety and efficacy of bimekizumab (BKZ) in patients with active ankylosing spondylitis (AS) up to 5 years of treatment in the phase 2b study BE AGILE and its open-label extension (OLE).